The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients
NCT ID: NCT00002336
Last Updated: 2015-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
INTERVENTIONAL
1992-11-30
1994-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS
NCT00000644
The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS
NCT00002331
The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients
NCT00001030
A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients
NCT00002309
A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
NCT00001058
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clarithromycin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HIV infection.
* CD4 count \<= 100 cells/mm3.
* No evidence of MAC.
* Life expectancy of at least 6 months.
Exclusion Criteria
Excluded:
* Certain restricted drugs (details not available).
Patients with the following prior conditions are excluded:
History of allergy or hypersensitivity to macrolides. Active substance abuse or other conditions that would affect study compliance.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univ of Arizona / Health Science Ctr
Tucson, Arizona, United States
California Med Research Group
Fresno, California, United States
HIV Research Group
San Diego, California, United States
Saint Francis Mem Hosp
San Francisco, California, United States
Kaiser Permanente Med Ctr
San Francisco, California, United States
Santa Clara Valley Med Ctr
San Jose, California, United States
TheraFirst Med Ctrs Inc
Fort Lauderdale, Florida, United States
Dr Nelson Zide
Hollywood, Florida, United States
Infectious Disease Research Institute Inc
Tampa, Florida, United States
Indiana Univ Hosp
Indianapolis, Indiana, United States
Saint Vincent's Hosp and Med Ctr
New York, New York, United States
SUNY / Health Sciences Ctr at Syracuse
Syracuse, New York, United States
New York Med College / Westchester County Med Ctr
Valhalla, New York, United States
Nalle Clinic
Charlotte, North Carolina, United States
Westover Heights Clinic
Portland, Oregon, United States
Univ of Tennessee
Memphis, Tennessee, United States
Vanderbilt Univ
Nashville, Tennessee, United States
Univ of Texas Southwestern Med Ctr of Dallas
Dallas, Texas, United States
Houston Veterans Administration Med Ctr
Houston, Texas, United States
Audie L Murphy Veterans Administration Hosp
San Antonio, Texas, United States
Salem Veterans Administration Med Ctr
Salem, Virginia, United States
Dr Alan D Tice / Infections Ltd
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, Wormser GP, Jablonowski H, Jemsek J, Cynamon M, Yangco BG, Notario G, Craft JC. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996 Aug 8;335(6):384-91. doi: 10.1056/NEJM199608083350603.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M91-561
Identifier Type: -
Identifier Source: secondary_id
124A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.